Glaxosmithkline | GSK - Zinsaufwendungen Für Schuld

Aktienkurs
53.41
Täglich Wechseln
-5.71 -9.66%
Monatlich
-12.70%
Jährlich
32.24%
Q1 Prognose
52.28




Zinsaufwendungen Für Schuld Veränderung Datum
AbbVie USD 740M 40M 2025-06
Amgen USD 653M 32M 2025-12
AstraZeneca USD 484M 181M 2025-12
Aurora Cannabis CAD 2.22M 442K 2025-09
Bausch Health Companies USD 412M 53M 2025-09
Bristol-Myers Squibb USD 432M 48M 2025-12
Canopy Growth CAD 8.8M 938K 2025-09
Corcept Therapeutics USD 823.61M 21.88M 2025-09
Drreddys Laboratories INR 944M 127M 2025-12
Eli Lilly USD 114.7M 134.3M 2025-09
GlaxoSmithKline GBP 188M 21M 2025-12
Glaxosmithkline GBP 177.95M 6.05M 2025-09
J&J USD 18M 290M 2025-09
Merck USD 412M 85M 2025-12
Novartis USD 281M 8M 2025-09
Pacira USD 3.89M 387K 2025-12
Perrigo USD 10.08B 10.04B 2025-09
Pfizer USD 711M 59M 2025-12
Phibro Animal Health USD 11.91M 191K 2025-12
Prestige Brands USD 10.67M 636K 2025-12
Roche Holding CHF 304M 7.5M 2025-06
Sanofi EUR -25M 252M 2025-12
Supernus Pharmaceuticals USD 910K 278K 2023-06
Takeda JPY 123.63B 40.49B 2025-12
Teva Pharmaceutical Industries USD 220M 17M 2025-12
Zoetis USD 57M 1000K 2025-12